The healthcare world is ablaze with news surrounding retatrutide, a potential peptide currently in investigation for excess conditions. Formulated by Zealand Pharma, retatrutide functions as a dual stimulator for both GLP-1 and GIP receptors, modulating appetite and glucose metabolism in a distin